Insmed (INSM)
(Delayed Data from NSDQ)
$71.69 USD
-1.17 (-1.61%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $72.05 +0.36 (0.50%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INSM 71.69 -1.17(-1.61%)
Will INSM be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INSM
Insmed (INSM) Reliance on International Sales: What Investors Need to Know
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Other News for INSM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)
Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)
Truist Financial Reaffirms Their Buy Rating on Insmed (INSM)
Insmed’s Strong Revenue Growth and Promising Pipeline Drive Buy Rating
Evercore ISI Reaffirms Their Buy Rating on Insmed (INSM)